Cleavage of macromolecular heparin by an enzyme from mouse mastocytoma - PubMed (original) (raw)
. 1975 Apr 10;250(7):2690-7.
- PMID: 804478
Free article
Cleavage of macromolecular heparin by an enzyme from mouse mastocytoma
S Ogren et al. J Biol Chem. 1975.
Free article
Abstract
Heparinase was isolated from a transplantable mouse mastocytoma, by salt extraction of a particulate fraction sedimenting at 20,000 times g, followed by precipitation from saturated ammonium sulfate. By use of gel chromatography through Sepharose 4B, the enzyme was shown to degrade macromolecular. 35S-labeled, mastocytomal heparin (K-av about 0.25) to products similar in size to commercial heparin (K-av about 0.85), apparently by nonrandom cleavage of a limited number of glycosidic linkages per molecule. Prolonged incubation times (up to 5 days, with repeated addition of enzyme) did not result in further degradation of the product. No significant depolymerizing activity was observed with any other glycosaminoglycan tested, including chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparan sulfate, and commercial heparin. The pH optimum for degradation of macromolecular heparin was around pH 5. The nature of the linkage cleaved by the heparinase was investigated by reduction of unlabeled polysaccharide degradation products with sodium [3H]borohydride. The degraded chains (but not the macromolecular substrate) incorporated significant amounts of tritium. An essentially monodisperse fraction of the labeled, degraded heparin was subjected to meniscus depletion sedimentation equilibrium ultracentrifugation, indicating a molecular weight of 14,500. By relating the molecular weight to the specific activity of the preparation, the amount of reducible groups was calculated to be approximately one per molecule. The 3H-labeled heparin was degraded to monosaccharides by a combination of acid hydrolysis and cleavage due to deamination with nitrous acid. Analysis of the degradation products, by paper electrophoresis and paper chromatography, showed a major radioactive component which behaved like L-gulonic acid. Since [3H]gulonic acid would be the expected reduction product of a polysaccharide molecule, containing a glucuronic acid residue in terminal position, these results tentatively suggest that the heparinase is an endoglucuronidase. By direct deaminative cleavage (no hydrolysis) of the 3H-labeled heparin, the glucosamine unit in penultimate position (i.e. adjacent to the [3H]gulonic acid residue) was shown to be 52% N-sulfated and 48% N-acetylated. As only 14% of the glucosamine was N-acetylated in the macromolecular heparin substrate, it is suggested that cleavage of this polysaccharide, by the heparinase, occurs in regions more abundant in N-acetylated glucosamine residues than other portions of the molecule. The possibility that formation and degradation of macromolecular heparin occurs also in mammalian species other than rodents in discussed.
Similar articles
- Macromolecular properties and end-group analysis of heparin isolated from bovine liver capsule.
Jansson L, Ogren S, Lindahl U. Jansson L, et al. Biochem J. 1975 Jan;145(1):53-62. doi: 10.1042/bj1450053. Biochem J. 1975. PMID: 127581 Free PMC article. - Biosynthesis of heparin. Studies on the microsomal sulfation process.
Höök M, Lindahl U, Hallén A, Bäckström G. Höök M, et al. J Biol Chem. 1975 Aug 10;250(15):6065-71. J Biol Chem. 1975. PMID: 807579 - Metabolism of macromolecular heparin in mouse neoplastic mast cells.
Ogren S, Lindahl U. Ogren S, et al. Biochem J. 1976 Mar 15;154(3):605-11. doi: 10.1042/bj1540605. Biochem J. 1976. PMID: 821471 Free PMC article. - Biosynthesis of heparin. Substrate specificity of heparosan N-sulfate D-glucuronosyl 5-epimerase.
Jacobsson I, Lindahl U, Jensen JW, Rodén L, Prihar H, Feingold DS. Jacobsson I, et al. J Biol Chem. 1984 Jan 25;259(2):1056-63. J Biol Chem. 1984. PMID: 6420398 - Preparation of heparin/heparan sulfate oligosaccharides.
Yamada S. Yamada S. 2021 Oct 6 [updated 2022 Mar 30]. In: Nishihara S, Angata K, Aoki-Kinoshita KF, Hirabayashi J, editors. Glycoscience Protocols (GlycoPODv2) [Internet]. Saitama (JP): Japan Consortium for Glycobiology and Glycotechnology; 2021–. 2021 Oct 6 [updated 2022 Mar 30]. In: Nishihara S, Angata K, Aoki-Kinoshita KF, Hirabayashi J, editors. Glycoscience Protocols (GlycoPODv2) [Internet]. Saitama (JP): Japan Consortium for Glycobiology and Glycotechnology; 2021–. PMID: 37590774 Free Books & Documents. Review. No abstract available.
Cited by
- Heparanase: A Challenging Cancer Drug Target.
Coombe DR, Gandhi NS. Coombe DR, et al. Front Oncol. 2019 Nov 28;9:1316. doi: 10.3389/fonc.2019.01316. eCollection 2019. Front Oncol. 2019. PMID: 31850210 Free PMC article. Review. - Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder.
Khoory MS, Nesheim ME, Bowie EJ, Mann KG. Khoory MS, et al. J Clin Invest. 1980 Mar;65(3):666-74. doi: 10.1172/JCI109712. J Clin Invest. 1980. PMID: 6444419 Free PMC article. - Protease, Growth Factor, and Heparanase-Mediated Syndecan-1 Shedding Leads to Enhanced HSV-1 Egress.
Karasneh GA, Kapoor D, Bellamkonda N, Patil CD, Shukla D. Karasneh GA, et al. Viruses. 2021 Sep 1;13(9):1748. doi: 10.3390/v13091748. Viruses. 2021. PMID: 34578329 Free PMC article. - Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I, Singh P, Boyango I, Gutter-Kapon L, Elkin M, Sanderson RD, Ilan N. Vlodavsky I, et al. Drug Resist Updat. 2016 Nov;29:54-75. doi: 10.1016/j.drup.2016.10.001. Epub 2016 Oct 6. Drug Resist Updat. 2016. PMID: 27912844 Free PMC article. Review. - Sanfilippo disease type D: deficiency of N-acetylglucosamine-6-sulfate sulfatase required for heparan sulfate degradation.
Kresse H, Paschke E, von Figura K, Gilberg W, Fuchs W. Kresse H, et al. Proc Natl Acad Sci U S A. 1980 Nov;77(11):6822-6. doi: 10.1073/pnas.77.11.6822. Proc Natl Acad Sci U S A. 1980. PMID: 6450420 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials